FGFR2 fusions as novel oncogenic drivers in gastrointestinal stromal tumors: Two case reports and review of literature

This article details two cases of KIT/PDGFRAwild-type GISTs. Next-generation sequencing revealed novel FGFR2 fusions (e.g., FGFR2-CIT/intergenic-FGFR2and FGFR2-CAMK2G/FGFR2-VCL). Both patients responded favorably to standard imatinib therapy and achieved sustained remission. These findings suggest FGFR2fusions act as primary oncogenic drivers in a rare GIST subset. Comprehensive genomic profiling is highlighted as important, and fibroblast growth factor receptor-targeted inhibitors may be a therapeutic strategy for advanced or imatinib-resistant disease.